Compare AMP & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | IDXX |
|---|---|---|
| Founded | 1894 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3B | 45.4B |
| IPO Year | 2009 | 1996 |
| Metric | AMP | IDXX |
|---|---|---|
| Price | $562.00 | $559.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $544.91 | ★ $721.67 |
| AVG Volume (30 Days) | 390.0K | ★ 599.8K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | 9.77 | ★ 22.59 |
| EPS | ★ 21.64 | 7.74 |
| Revenue | ★ $18,911,000,000.00 | $4,303,702,000.00 |
| Revenue This Year | $1.79 | $10.88 |
| Revenue Next Year | $4.20 | $8.59 |
| P/E Ratio | ★ $25.93 | $72.29 |
| Revenue Growth | 5.49 | ★ 10.42 |
| 52 Week Low | $422.37 | $518.55 |
| 52 Week High | $572.56 | $769.98 |
| Indicator | AMP | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 47.93 |
| Support Level | $450.79 | $536.34 |
| Resistance Level | $572.56 | $583.93 |
| Average True Range (ATR) | 10.26 | 17.11 |
| MACD | -3.10 | -2.68 |
| Stochastic Oscillator | 54.25 | 30.11 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.